Metastatic castrate-resistant prostate cancer: dawn of a new age of management

BJU International
Susan Masson, Amit Bahl

Abstract

What's known on the subject? and What does the study add? Metastatic castrate-resistant prostate cancer (mCRPC) was historically considered to be an aggressive disease resistant to conventional anticancer therapy. Within the last decade the outlook has changed beyond recognition; docetaxel chemotherapy is now firmly established as a well-tolerated treatment with significant survival benefits. Building on this, more recently there have been several landmark developments using various approaches in patients whose disease has progressed despite previous chemotherapy. Cabazitaxel chemotherapy offers survival and health-related quality of life (HRQL) improvements in this setting, as does the CYP inhibitor abiraterone acetate. Significant clinical benefits are also seen with novel radioisotope and immunotherapeutic approaches. There have been many developments in the management of this condition within the last 2 years, with several landmark studies showing new treatments that offer survival and HRQL benefits even in the setting of advanced disease, which has been heavily pretreated. This review article summarises these important developments and gives the reader an overview of current practice, recent changes and future directions. ...Continue Reading

References

Jul 27, 2001·Current Pharmaceutical Design·M C Bissery
Apr 15, 2004·Endocrine Reviews·Cynthia A Heinlein, Chawnshang Chang
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 9, 2007·European Urology·Axel HeidenreichUNKNOWN European Association of Urology
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dominik R BertholdIan F Tannock
Apr 26, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·X PivotJ P Lotz
Nov 18, 2008·Expert Opinion on Investigational Drugs·Kim N ChiMartin E Gleave
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alain C MitaAnthony W Tolcher
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Jul 28, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G SonpavdeT E Hutson
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergMarcel Rozencweig
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Oct 5, 2010·Lancet·Tanya B Dorff, David I Quinn
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Nov 15, 2011·The Journal of Urology·Patrick C Walsh

❮ Previous
Next ❯

Citations

May 20, 2014·Oncogene·F Valdés-Mora, S J Clark
Jul 23, 2016·Nature Reviews. Drug Discovery·Timothy A YapJohann S de Bono
Dec 3, 2016·Experimental Biology and Medicine·Ahmed A MoustafaAsim B Abdel-Mageed
Jun 23, 2018·Experimental Biology and Medicine·Ahmed A MoustafaAsim B Abdel-Mageed
Aug 11, 2012·Bulletin du cancer·Stéphanie Lheureux, Florence Joly

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
J A Harrington, R J Jones
© 2021 Meta ULC. All rights reserved